Pulmonary arterial hypertension (PAH) is a chronic, progressive, and debilitating disease
associated with increased cardiopulmonary morbidity and mortality. Current knowledge is …

Rationale: There is a noticeable underrepresentation of minorities in clinical trials and
registries in pulmonary arterial hypertension (PAH). Prior studies evaluating the association …

There is increasing awareness on the significance of socioeconomic status, social
determinants of health, and the role of ethnicity and race in clinical outcomes of patients with …

Minoritized racial and ethnic groups suffer disproportionately from the incidence and
morbidity of pulmonary hypertension (PH), as well as its associated cardiovascular …

Rationale: Limited information is available on racial/ethnic differences in pulmonary arterial
hypertension (PAH). Objectives: Determine effects of race/ethnicity and ancestry on mortality …

Background: dependent on early diagnosis and institution of therapy. To date, little work has
been done to determine whether Hispanics in the US affected by PAH are at higher risk of …

In the past decade and a half, the introduction of new therapeutic agents has revolutionized
the management of pulmonary arterial hypertension (PAH). These new treatment options …

The Black Lives Matter protests and COVID-19 pandemic have brought widening disparities
experienced by disadvantaged communities of color to the forefront, generating much …

Background: Health disparities have a major impact in the quality of life and clinical care
received by minorities in the United States. Pulmonary arterial hypertension (PAH) is a rare …

OBJECTIVES: Pulmonary hypertension portends a poorer prognosis for blacks versus white
populations, but the underlying reasons are poorly understood. We investigated …